Hunan Fangsheng Pharmaceutical (603998.SH): The clinical trial of Rulogoli tablets has been approved.
Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "...
Hunan Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng") received approval from the National Medical Products Administration for the research and development project of Rilugolix tablets, a chemical generic drug. The approval allows the product to conduct clinical trials for prostate cancer.
Related Articles
QINIU (02567) management and cornerstone investors voluntarily extend the lock-up period by one year, with the increase in AI users indicating a new growth curve.
GMTEight List of A-share restricted sales and lifting restrictions | October 16th
POWER XINCHEN (01148) will be temporarily suspended from trading starting October 16th, awaiting the publication of insider information.
QINIU (02567) management and cornerstone investors voluntarily extend the lock-up period by one year, with the increase in AI users indicating a new growth curve.
GMTEight List of A-share restricted sales and lifting restrictions | October 16th
POWER XINCHEN (01148) will be temporarily suspended from trading starting October 16th, awaiting the publication of insider information.
